Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
US9174981B2 · kind B2 · utility
3Cited by
0References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2011 |
| Grant date | Nov 3, 2015 |
| Priority date | — |
| Expiry date | Dec 13, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.